Hemorrhagic cystitis induced by JC polyomavirus infection following COVID-19: a case report

Yuanjie Lv1, Xiaoping Liu2

  • 1Department of Infection, Hospital of Traditional Chinese Medicine, Xinchang County, No.188 Shijiu Feng Road, Qixing Street, Shaoxing, 312500, China. lvyuanjie134@163.com.

BMC Urology
|April 16, 2024
PubMed

Insights

JC polyomavirus (JCPyV) can cause urinary tract disease in immunocompromised patients, as seen in a COVID-19 case. Rapid diagnosis via metagenomic sequencing led to effective treatment with immunoglobulin therapy.

Area of Science:

  • Virology
  • Immunology
  • Urology

Background:

  • JC polyomavirus (JCPyV) establishes persistent infections, typically asymptomatic in immunocompetent individuals.
  • JCPyV is primarily associated with central nervous system diseases like progressive multifocal leukoencephalopathy (PML) in immunosuppressed patients.
  • While JCPyV resides in the kidney-urinary tract, its role in urinary system diseases is exceptionally rare.

Observation:

  • A 60-year-old male with COVID-19 developed hemorrhagic cystitis after treatment with nirmatrelvir/ritonavir.
  • Metagenomic next-generation sequencing (mNGS) identified JCPyV type 2 as the causative agent.
  • Intravenous human immunoglobulin (PH4) therapy resulted in the resolution of hematuria within three days.

Findings:

  • This case demonstrates JCPyV's potential pathogenicity in the urinary system, beyond its known neurological effects.
  • The study highlights the importance of considering JCPyV in urinary tract infections, particularly in immunocompromised hosts.
  • Metagenomic next-generation sequencing (mNGS) proved crucial for rapid and accurate diagnosis of the infectious etiology.

Implications:

  • The findings suggest that JCPyV should be considered in the differential diagnosis of hemorrhagic cystitis in immunocompromised individuals.
  • Rapid diagnostic tools like mNGS can significantly improve patient outcomes by enabling timely and targeted therapies.
  • This case expands the understanding of JCPyV's clinical manifestations and the utility of immunoglobulin therapy in managing JCPyV-associated diseases.

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Burn Injuries01:22

Burn Injuries

Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...